checkAd

     169  0 Kommentare The era of biosolutions. Outlook upgraded for 2024

    Novonesis is performing very well and the 2024 outlook for pro forma organic sales growth is now expected at the upper end of the 5-7% range while the pro forma adjusted EBITDA margin is increased to 35-36%.

    Novonesis’ Capital Markets Day on June 18, 2024 will provide an introduction to Novonesis with insights on how the company intends to capture and accelerate organic sales growth. Also, Novonesis maintains the target for organic sales growth at 6-8% CAGR through 2025 with an adjusted EBITDA margin of ~37% and reconfirms the ambition to further accelerate organic sales growth beyond 2025.

    Ester Baiget, President & CEO: “Demand for sustainable biosolutions will continue to grow stronger as the world needs answers to the increasing need to feed and fuel a growing world sustainably. The seamless integration of our two companies has already created a stronger foundation to capture and accelerate growth in the attractive biosolutions space. We are committed to leading the transformation of societies and economies to secure healthier lives and a healthier planet.”

    Novonesis’ biosolutions are already present in peoples’ everyday lives, reaching more than half the world’s population. A growing population, increasing energy needs, evolving nutritional and health trends and climate risks create strong and increasing demand for sustainable biosolutions. Novonesis is uniquely positioned with strong customer relationships and an understanding of customer needs, a broad biosolutions toolbox, as well as the unique ability to up-scale and produce robust and affordable biosolutions. The foundation is in place to leverage our capabilities with clear prioritization and focused execution to deliver on the full potential. This enables the confirmation of targets until 2025 with an ambition to further accelerate profitable organic sales growth thereafter.

    • 2024 outlook of pro forma organic sales growth now expected at the upper end of the 5-7% range.
    • Cost synergy implementation ahead of plan with a run rate of ~80% by the end of June 2024.
    • 2024 pro forma adjusted EBITDA margin increased to 35-36% from previously ~35%.
    • Expected organic sales growth at 6-8% CAGR through 2025 maintained, driven by volume, price and synergies.
    • Adjusted EBITDA margin maintained at ~37% by 2025.
    • Reconfirmation of the sales synergy target of EUR 200m run-rate four years after completion of the combination and the cost synergy target of EUR 80-90m run-rate three years after completion of the combination.
    • Margin expansion supported by strong focus on productivity improvements and economies of scale as well as synergies.
    • Beyond 2025, ambition to deliver accelerated sustainable organic sales growth from the underlying business coupled with new, and de-risked, innovation and growth opportunities.
    • EPS accretion for the combination with Chr. Hansen maintained at mid-single digit percentage in third year after completion.
    • A clear capital allocation model with an expected dividend payout ratio of 40-60%.
    • Dedication to a sustainable future with clear non-financial targets and commitments.
    • As the current long-term financial targets only run to 2025, new long-term financial targets are expected to be communicated in 2H 2025.

    Event information

    Seite 1 von 3


    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    The era of biosolutions. Outlook upgraded for 2024 Novonesis is performing very well and the 2024 outlook for pro forma organic sales growth is now expected at the upper end of the 5-7% range while the pro forma adjusted EBITDA margin is increased to 35-36%. Novonesis’ Capital Markets Day on June …